Faculty

Institution

Unit

Venue

Sumit K. Subudhi

The University of Texas MD Anderson Cancer Center

Affiliations

Division Of Medical Oncology

The University of Texas MD Anderson Cancer Center

Sumit K. Subudhi is a Senior Professor at The University of Texas MD Anderson Cancer Center, specializing in genitourinary medical oncology. His research focuses on prostate cancer immunotherapy, tumor immunology, and the development of novel combination strategies, including T cell engagers and bispecific antibodies. His recent work investigates the influence of adiposity and body composition on treatment efficacy, the co-evolution of cancer cells and their microenvironment under androgen deprivation therapy, and phase trials optimizing PSMAxCD28 costimulatory bispecific antibodies with anti-PD-1 checkpoint inhibition in metastatic castration-resistant prostate cancer.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Sumit K. Subudhi

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

oncology prostate cancer urology cancer care immunology pharmacology cancer immunotherapy cancer research cancer treatment immunotherapy genitourinary cancers medicinal research prostatic disease pharmacotherapy medicine clinical research immune checkpoint inhibitors cellular therapy immune responses cancer cells oncogenes molecular cancer clinical trials clinical immunology tumor targeting cancer biology anti-cancer agents cancer discovery therapeutic efficacy experimental medicine cancer management jama oncology surgical oncology drug trials endocrine-related cancers cellular immune responses cancer immunosurveillance t-regulatory cell immunosuppression prognostic biomarkers vascular biology adaptive immune system immunomodulation immunologic diseases immune checkpoint therapy immune-related adverse events medical mycology therapy resistance tumor suppressors novel therapies benign prostatic hyperplasia metastatic prostate cancer phase ii study castration-resistant prostate cancer viral oncology molecular immunology clinical evidence treatment options metastasis-directed therapy localized prostate cancer immunotherapy resistance cell transplantation thoracic oncology clinical proteomics drug targeting cardiac pathologies endocrine oncology brachytherapy immune-mediated colitis oligometastatic prostate cancer finite abiraterone acetate future directions androgen receptor blockade next decade inhibitory immune checkpoint ipilimumab therapy

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 6159: Co-Evolution of Cancer Cells and Their Microenvironment of Primary and Lymph Node Metastatic Prostate Cancer Under Androgen Deprivation Therapy. Cancer Research (2026)

oncogenesmetastasiscancer cellsandrogen deprivation therapycell biologygenitourinary cancersprostate cancerprostatic diseaseabstract 6159tumor microenvironmenturologytumor heterogeneitycancer careoncologycancer biology

Adiposity and Response to Adt ± Ar Pathway Inhibitors (Arpi) in Men With Metastatic Hormone-Sensitive Prostate Cancer (Mhspc).. Journal of Clinical Oncology (2026)

metabolic syndromecancer careoncologygenitourinary cancersprostate cancerprostatic diseasepharmacologymetabolic disordersurologyhealth sciencesobesityobesity medicine

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy With Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. European Urology (2026)

metastasiscancer caredefinitive treatmentcancer treatmentphase 2genitourinary cancersprostate cancerprostatic diseasemedicineurologyprimary tumorpharmacotherapyclinical trialsoncology

Cardiometabolic Health’s Influence on Outcomes in Men With Localized High-Risk Prostate Cancer (Hrpca) Treated With Pre-Operative Adt ± Ar Pathway Inhibition (Arpi).. Journal of Clinical Oncology (2026)

cardiovascular diseasecardiovascular researchcardiometabolic health ’genitourinary cancersprostate cancerprostatic diseasemedicineurologycancer careoncology

HYPERVIGILANCE: A Phase Ib Clinical Trial to Optimize Risk-Benefit of Nezastomig (Psmaxcd28 Costimulatory Bispecific Antibody) Plus Cemiplimab (Anti-Pd-1) in Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc).. Journal of Clinical Oncology (2026)

cancer carecancer treatmentgenitourinary cancersprostate cancerprostatic diseasemedicineurologypharmacotherapyclinical trialsoncology

Influence of Body Composition on the Efficacy of Chemotherapy in Men With Metastatic Aggressive Variant Prostate Cancer (Avpc).. Journal of Clinical Oncology (2026)

metastasiscancer carebody compositiongenitourinary cancersprostate cancerprostatic diseasejama oncologycancer managementurologyhealth sciencesoncology

The Path Forward for T Cell Engagers in Patients With Prostate Cancer. The Medicine Forum (2026)

cancer cellscell therapycancer immunotherapyt cell engagersimmunologyimmunotherapyprostate cancercellular therapygenitourinary cancersprostatic diseasepath forwardcancer immunosurveillanceurology

1057 Early Targeted Biologics Are Associated With Improved Clinical Outcomes in Immune-Related Myocarditis, Myositis, and Myasthenia Gravis. Regular and Young Investigator Award Abstracts (2025)

immunologic diseasesinflammationinflammatory diseasesmyositisimmunologyrheumatismimmunotherapyimmune responsesmyasthenia gravismedicineautoimmune diseasesimmune-related myocarditisautoimmunityimproved clinical outcomesclinical rheumatology

1064 Clinical and Prognostic Characterization of High-Grade Neurologic Immune-Related Adverse Events in Patients With Urinary Cancers. Regular and Young Investigator Award Abstracts (2025)

bladder cancerurinary cancersclinical rheumatologyimmunologyurological researchimmunotherapycellular therapygenitourinary cancersprognostic characterizationcancer researchcancer immunosurveillanceurologycancer careoncology

153 Association of Candidate Tertiary Lymphoid Structures in Baseline Tumor Tissue With Response to Ipilimumab in Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc). Regular and Young Investigator Award Abstracts (2025)

oncogenesmetastasisradiation oncologygenitourinary cancersprostate cancerprostatic diseasebaseline tumor tissuecancer discoveryjama oncologytherapeutic targetsurologyimmune checkpoint inhibitorsoncology

1
2
3
4
5
17
10 / page

Sumit K. Subudhi

The University of Texas MD Anderson Cancer Center

Affiliations

Division Of Medical Oncology

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Sumit K. Subudhi

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 6159: Co-Evolution of Cancer Cells and Their Microenvironment of Primary and Lymph Node Metastatic Prostate Cancer Under Androgen Deprivation Therapy. Cancer Research (2026)

Adiposity and Response to Adt ± Ar Pathway Inhibitors (Arpi) in Men With Metastatic Hormone-Sensitive Prostate Cancer (Mhspc).. Journal of Clinical Oncology (2026)

metabolic syndromecancer careoncologygenitourinary cancersprostate cancerprostatic diseasepharmacologymetabolic disordersurologyhealth sciencesobesityobesity medicine

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy With Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer. European Urology (2026)

metastasiscancer caredefinitive treatmentcancer treatmentphase 2genitourinary cancersprostate cancerprostatic diseasemedicineurologyprimary tumorpharmacotherapyclinical trialsoncology

cardiovascular diseasecardiovascular researchcardiometabolic health ’genitourinary cancersprostate cancerprostatic diseasemedicineurologycancer careoncology

cancer carecancer treatmentgenitourinary cancersprostate cancerprostatic diseasemedicineurologypharmacotherapyclinical trialsoncology

Influence of Body Composition on the Efficacy of Chemotherapy in Men With Metastatic Aggressive Variant Prostate Cancer (Avpc).. Journal of Clinical Oncology (2026)

metastasiscancer carebody compositiongenitourinary cancersprostate cancerprostatic diseasejama oncologycancer managementurologyhealth sciencesoncology

The Path Forward for T Cell Engagers in Patients With Prostate Cancer. The Medicine Forum (2026)

cancer cellscell therapycancer immunotherapyt cell engagersimmunologyimmunotherapyprostate cancercellular therapygenitourinary cancersprostatic diseasepath forwardcancer immunosurveillanceurology

1057 Early Targeted Biologics Are Associated With Improved Clinical Outcomes in Immune-Related Myocarditis, Myositis, and Myasthenia Gravis. Regular and Young Investigator Award Abstracts (2025)

1064 Clinical and Prognostic Characterization of High-Grade Neurologic Immune-Related Adverse Events in Patients With Urinary Cancers. Regular and Young Investigator Award Abstracts (2025)

1
2
3
4
5
17
10 / page